Brain tumors in patients with myotonic dystrophy: a population‐based study

Patients with myotonic dystrophy (DM) are at high risk of brain cancer. This study describes the spectrum of brain neoplasms in DM patients.

[1]  M. Greene,et al.  Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis , 2013, PloS one.

[2]  P. Kaminsky,et al.  Augmentation du risque de tumeurs dans la dystrophie myotonique de type 1 , 2013 .

[3]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[4]  Kimberly J. Johnson,et al.  Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. , 2012, Neuro-oncology.

[5]  Damien C Weber,et al.  Epidemiology of glial and non-glial brain tumours in Europe. , 2012, European journal of cancer.

[6]  M. Sant,et al.  Survival of European patients with central nervous system tumors , 2012, International journal of cancer.

[7]  M. Greene,et al.  Correlates of tumor development in patients with myotonic dystrophy , 2012, Journal of Neurology.

[8]  Aung Ko Win,et al.  Increased cancer risks in myotonic dystrophy. , 2012, Mayo Clinic proceedings.

[9]  M. Greene,et al.  Cancer risk among patients with myotonic muscular dystrophy. , 2011, JAMA.

[10]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[11]  S. Lönn,et al.  Two-year survival of low-grade and high-grade glioma patients using data from the Swedish Cancer Registry , 2011, Acta Neurochirurgica.

[12]  C. Angelini,et al.  Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2 , 2010, Journal of Neurology.

[13]  Tyson A. Clark,et al.  Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy , 2010, Nature Structural &Molecular Biology.

[14]  G. Meola,et al.  Cerebral involvement in myotonic dystrophies , 2007, Muscle & nerve.

[15]  M. Schoenfeld,et al.  Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1 , 2006, Muscle & nerve.

[16]  Hung-Chou Kuo,et al.  Brain magnetic resonance image changes in a family with congenital and classic myotonic dystrophy , 2005, Brain and Development.

[17]  K. Ito,et al.  Diffusion tensor imaging of cerebral white matter in patients with myotonic dystrophy , 2005, Acta radiologica.

[18]  C. Mainero,et al.  Cerebral atrophy in myotonic dystrophy: a voxel based morphometric study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  T. Klockgether,et al.  Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2 , 2004, Journal of Neurology.

[20]  V. Coviello,et al.  Cumulative Incidence Estimation in the Presence of Competing Risks , 2004 .

[21]  M. Brenner,et al.  Alexander's Disease , 2003, Journal of child neurology.

[22]  H. Grönberg,et al.  Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first‐degree relatives of brain tumour patients , 2003, International journal of cancer.

[23]  F. Di Salle,et al.  Pattern and significance of white matter abnormalities in myotonic dystrophy type 1: an MRI study , 2002, Journal of Neurology.

[24]  S. Naylor,et al.  Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9 , 2001, Science.

[25]  D. Perani,et al.  Reduced cerebral blood flow and impaired visual–spatial function in proximal myotonic myopathy , 1999, Neurology.

[26]  J. Parisi,et al.  A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma , 1993, Neurology.

[27]  T. Ashizawa,et al.  An unstable triplet repeat in a gene related to myotonic muscular dystrophy. , 1992, Science.

[28]  C. Amemiya,et al.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. , 1992, Science.

[29]  David E. Housman,et al.  Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member , 1992, Cell.

[30]  A. Bewley,et al.  Dysplastic nevi, cutaneous melanoma, and other skin neoplasms in patients with myotonic dystrophy type 1: a cross-sectional study. , 2015, Journal of the American Academy of Dermatology.

[31]  B. Echenne,et al.  Congenital and infantile myotonic dystrophy. , 2013, Handbook of clinical neurology.

[32]  P. Kaminsky,et al.  [Increasing risk of tumors in myotonic dystrophy type 1]. , 2013, Presse medicale.

[33]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[34]  A. Kyritsis,et al.  Inherited predisposition to glioma. , 2010, Neuro-oncology.

[35]  T. Cooper,et al.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. , 2006, Progress in molecular and subcellular biology.

[36]  E. Nanba,et al.  [Myotonic dystrophy]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[37]  B. Assouline,et al.  Familial aggregation of malignant melanoma/dysplastic naevi and tumours of the nervous system: an original syndrome of tumour proneness. , 1997, Annales de genetique.

[38]  B Mattsson,et al.  Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. , 1984, Acta radiologica. Oncology.